Overview

A Clinical Trial for CTD-ILD Treatment

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University of Michigan

Treatments:

Acetylcysteine
N-monoacetylcystine